Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 1.00 |
| ▸ | CNR2 | P34972 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | FAAH | O00519 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL496000 | 1.00 | CNR1 (1.00) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL3690975 | 1.00 | CNR1 (1.00) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL12023406 | 0.98 | CNR1 (0.97) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL4645046 | 0.98 | CNR1 (0.97) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL14864045 | 0.93 | CNR1 (0.88) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL2218546 | 0.93 | CNR1 (0.87) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL2218540 | 0.93 | CNR1 (0.87) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL4743609 | 0.92 | CNR1 (0.85) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL12023424 | 0.92 | CNR1 (0.85) | CNR1CNR2ALDH1A1FAAHMAPT | |
| Water SCHEMBL11118961 | 0.91 | CNR1 (0.84) | CNR1CNR2ALDH1A1FAAHMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1534 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4281046-B1 | NALTREXONE COMPOSITIONS | LDN PHARMA LTD (GB) | 2025-09-10 | — | — | EP | claimed |
| US-12370230-B2 | Hemp and PEA formulation and its use | Metagenics LLC (US) | 2025-07-29 | — | — | US | claimed |
| US-20250222189-A1 | Blood And Toxin Filter Device And Use Of Same | CYTOSORBENTS CORPORATION | 2025-07-10 | — | — | US | claimed |
| EP-3200805-B1 | USE OF GASTROINTESTINALLY ADMINISTERED POROUS ENTERON SORBENT POLYMERS TO PREVENT OR TREAT RADIATION INDUCED MUCOSITIS, ESOPHAGITIS, ENTERITIS, COLITIS, AND GASTROINTESTINAL ACUTE RADIATION SYNDROME | CYTOSORBENTS CORP (US) | 2025-07-02 | — | — | EP | claimed |
| EP-4486336-A2 | CB1 LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | Adarx Pharmaceuticals, Inc. (US) | 2025-01-08 | — | — | EP | claimed |
| US-20240390502-A1 | DELIVERY SYSTEMS FOR BIOACTIVE LIPIDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2024-11-28 | — | — | US | claimed |
| EP-4380555-A1 | COMPOSITION COMPRISING MANNOSE, N-ACETYLCYSTEINE AND AT LEAST ONE ENDOCANNABINOID AND ITS USE FOR THE TREATMENT OF URIRNARY TRACT INFECTIONS | Agave S.r.l. (IT) | 2024-06-12 | — | — | EP | claimed |
| EP-4041748-B1 | PEPTIDE COMPOUNDS FOR REDUCING SIDE EFFECTS OF CB1 RECEPTOR AGONISTS | UNIV BARCELONA (ES) | 2024-05-01 | — | — | EP | claimed |
| WO-2023168296-A2 | CB1 LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-09-07 | — | — | WO | claimed |
| WO-2023049791-A1 | DELIVERY SYSTEMS FOR BIOACTIVE LIPIDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-03-30 | — | — | WO | claimed |
| US-20020072539-A1 | 2-Arachidonylglycerol (2-AG)-an inhibitor of tumor necrosis factor-alpha and neuroprotector of brain in closed head injury | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-06-13 | — | — | US | claimed |
| US-20020064804-A1 | Compositions and methods for detecting and quantifying COX-2 activity and 2-arachidonylglycerol metabolites | VANDERBILT UNIVERSITY | 2002-05-30 | — | — | US | claimed |
| US-20020019444-A1 | Anandamide and structurally related lipids as vanilloid receptor modulators | HOGESTATT EDWARD (SE) | 2002-02-14 | — | — | US | claimed |
| WO-2002012549-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING COX-2 ACTIVITY AND 2-ARACHIDONYLGLYCEROL METABOLITES | VANDERBILT UNIVERSITY (US) | 2002-02-14 | — | — | WO | claimed |
| WO-2001097793-A2 | 2-ARACHIDONYLGLYCEROL (2-AG) - AN INHIBITOR OF TUMOR NECROSIS FACTOR -ALFA AND NEUROPROTECTOR OF BRAIN IN CLOSED HEAD INJURY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2001-12-27 | — | — | WO | claimed |
| WO-2001085158-A2 | ANANDAMIDE AND STRUCTURALLY RELATED LIPIDS AS VANILLOID RECEPTOR MODULATORS | FORSKARPATENT I SYD AB (SE) | 2001-11-15 | — | — | WO | claimed |
| WO-2001028588-A1 | CANNABINOIDS AS VASODILATORS AND CARDIOPROTECTORS AGAINST ISCHEMIA | UNIVERSITE DE MONTREAL (CA) | 2001-04-26 | — | — | WO | claimed |
| WO-2001001980-A1 | METHODS FOR THE AMELIORATION OF NEUROPSYCHIATRIC DISORDERS BY INHIBITING THE INACTIVATING TRANSPORT OF ENDOGENOUS CANNABINOID SUBSTANCES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-01-11 | — | — | WO | claimed |
| EP-1066235-A1 | SYNTHETIC ENDOGENOUS CANNABINOID ANALOGUES AND USES THEREOF | Yissum Research And Development Company Of The Hebrew University Of Jerusalem (IL) | 2001-01-10 | — | — | EP | claimed |
| WO-1999051560-A1 | SYNTHETIC ENDOGENOUS CANNABINOIDS ANALOGUES AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1999-10-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019444-A1 | Anandamide and structurally related lipids as vanilloid receptor modulators | TRPV1, CNR2, CNR1 | CNR1 3/4885CNR2 2/4885ALDH1A1 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.